ERBB2 and Langer mesomelic dysplasia: LMD was independently associated with CNS-related death and shorter OS, as has been previously demonstrated.23,24,25 Limited data on new anti-ERBB2 agents among patients with LMD are available, and our findings support the urgent clinical need for clinical trials focusing on this population in the prevention, screening, and treatment domains.